News

November 11, 2019November 11, 2019

Hemophilia Patients, Caregivers Identify Factors That Influence Decision to Switch Treatments

News

Ease of use, fear of the unknown, and healthcare providers’ advice are all major factors that play a role in whether people with hemophilia want to switch to new ... Read more

November 8, 2019November 8, 2019

Updated Alta Trial Results Support Advancement of SB-525 Gene Therapy for Hemophilia A

News

Updated results from the Alta trial show that a single infusion with the highest dose of SB-525, an investigational gene therapy, yields dose-dependent and durable increases in clotting factor ... Read more

November 6, 2019November 6, 2019

uniQure Granted US Patent to Use FIX-Padua for Hemophilia B Gene Therapy

News

The U.S. Patent and Trademark Office has granted uniQure a third patent covering the formulation and use of the company’s factor IX Padua gene therapy for the treatment of hemophilia and ... Read more

November 4, 2019November 4, 2019

Anticoagulant Protein TFPI Crucial to Bleeding Severity Profile of Hemophilia Patients, Study Says

News

A natural anticoagulant protein called tissue factor pathway inhibitor (TFPI) is critical for defining the bleeding severity profiles of people with hemophilia A and B, researchers in France report. ... Read more

November 1, 2019November 1, 2019

Promising Interim Results Reported for uniQure’s Gene Therapy AMT-061 in Phase 2b Hemophilia B Trial

News

A single injection of uniQure‘s gene therapy AMT-061 (etranacogene dezaparvovec) is well-tolerated, effectively increases the levels of clotting factor IX (FIX), and completely prevents bleedings without the need for ... Read more

October 30, 2019October 30, 2019

Professional Help Essential for Parents Telling Daughters of Hemophilia Carrier Risk, Study Reports

News

An interview-based study from Japan found professional support was necessary when mothers inform their daughters they might be carriers for hemophilia, as the women found themselves “not knowing what ... Read more

October 28, 2019October 28, 2019

Older Hemophilia Patients have Lower Rates of Multiple Medication Use than Their Peers, Study Reports

News

Older patients with hemophilia have lower rates of polypharmacy, or use of multiple medications, and of drug-drug interactions than people of the same age without the disease, a review ... Read more

October 25, 2019October 25, 2019

Elimination of HCV in People with Bleeding Disorders Surpasses WHO Goals, Study Finds

News

Direct‐acting antiviral (DAA) therapy is especially effective at eliminating hepatitis C virus (HCV) in people with bleeding disorders, including hemophilia, a study has found. The study, “Elimination of hepatitis ... Read more

October 23, 2019October 23, 2019

Hemlibra Safe, Effective in Kids with Hemophilia A Regardless of Inhibitor Status, Data Show

News

Prophylactic (preventive) treatment with Hemlibra (emicizumab) safely and effectively reduces bleeding rates in children younger than 12 with hemophilia type A, regardless of development of inhibitors (antibodies) against synthetic factor ... Read more

October 21, 2019October 21, 2019

Fitbit Can Be Used to Track Physical Activity in People with Hemophilia, Study Finds

News

The Fitbit wristband can help with the continuous monitoring of physical activity in people with hemophilia, but other strategies are needed to encourage increased activity, a study suggests. The ... Read more

Pin It on Pinterest